Multi-layer Tablet: Current scenario and recent advances

The purpose of this article on tableting of multiple Active Pharmaceutical Ingredients (APIs) in the single oral solid dose in the form of Fixed Dose Combinations (FDCs), that focused on therapeutic justification, designing, its practical approach, summarize the problem encountered and parameters to be considered during development. This will help budding formulation development scientists working on generic development as such types of formulation is current need in various disease conditions. Looking to the necessity of medical practitioners, ultimately generic pharmaceutical companies taking interest in development of such formulation with correct medical justification due to various health problem not only in India but also globally. FDCs are highly popular in the Indian pharmaceutical market and also have been seen in the last few years. Presently very few generic companies are working on FDCs in the form of multilayer tablets resulting into small numbers of formulation in the market yearly.

[1]  R. Nagaraju,et al.  Formulation and Evaluation of Bilayer Sustained Release Tablets of Salbutamol and Theophylline , 2009 .

[2]  L. Saha,et al.  Fixed dose drug combinations (FDCs): rational or irrational: a view point. , 2008, British journal of clinical pharmacology.

[3]  Emad B. Basalious,et al.  Optimization and In vivo Pharmacokinetic Study of a Novel Controlled Release Venlafaxine Hydrochloride Three-Layer Tablet , 2010, AAPS PharmSciTech.

[4]  Shajahan Abdul,et al.  A flexible technology for modified release of drugs: multi layered tablets. , 2004, Journal of controlled release : official journal of the Controlled Release Society.

[5]  V. Satyanarayana,et al.  Three-layer guar gum matrix tablet formulations for oral controlled delivery of highly soluble trimetazidine dihydrochloride. , 2002, Journal of controlled release : official journal of the Controlled Release Society.

[6]  V. Pillay,et al.  A Review of Multi-Responsive Membranous Systems for Rate-Modulated Drug Delivery , 2010, AAPS PharmSciTech.

[7]  Y. Choi,et al.  A novel three-layered tablet for extended release with various layer formulations and in vitro release profiles , 2011, Drug development and industrial pharmacy.

[8]  Beom-Jin Lee,et al.  Formulation, release characteristics and bioavailability of novel monolithic hydroxypropylmethylcellulose matrix tablets containing acetaminophen. , 2005, Journal of controlled release : official journal of the Controlled Release Society.

[9]  A. Falcão,et al.  In‐vivo evaluation of prolonged release bilayer tablets of anti‐Parkinson drugs in Göttingen minipigs , 2011, The Journal of pharmacy and pharmacology.

[10]  M. Efentakis,et al.  Formulation Study and Evaluation of Matrix and Three-layer Tablet Sustained Drug Delivery Systems Based on Carbopols with Isosorbite Mononitrate , 2008, AAPS PharmSciTech.

[11]  Sarfaraz Niazi,et al.  Handbook of Pharmaceutical Manufacturing Formulations: Uncompressed Solid Products , 2009 .

[12]  R. Parikh,et al.  Fabrication and Evaluation of Bi-layer Tablet Containing Conventional Paracetamol and Modified Release Diclofenac Sodium , 2010, Indian journal of pharmaceutical sciences.

[13]  D. Misra,et al.  FDC of montelukast with levocetirizine: focus on bilayer technology. , 2009, Journal of the Indian Medical Association.

[14]  A. Cuitiño,et al.  Evaluation of the Performance Characteristics of Bilayer Tablets: Part I. Impact of Material Properties and Process Parameters on the Strength of Bilayer Tablets , 2012, AAPS PharmSciTech.

[15]  S. Gattani,et al.  Formulation and Evaluation of Bi-layer Tablet of Metoclopramide Hydrochloride and Ibuprofen , 2008, AAPS PharmSciTech.

[16]  S. Saisivam,et al.  Bilayer tablets of atorvastatin calcium and nicotinic acid: formulation and evaluation. , 2008, Chemical & pharmaceutical bulletin.

[17]  N. Pourkavoos Unique Risks, Benefits, and Challenges of Developing Drug-Drug Combination Products in a Pharmaceutical Industrial Setting , 2012 .